Opticol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Opticol

Property Description
Active ingredient Chloramphenicol
Form Sterile Ophthalmic Solution (Eye Drops)
Pharmacological class Broad-Spectrum Antibiotic, Anti-infective Agent
Common use Addressing Bacterial Ocular Infections
Origin Synthetic Drug (Nitrophenol Derivative)

What Type of Medicine Is Opticol?

Opticol is a medicine whose active component is Chloramphenicol, classified as a potent, synthetic broad-spectrum antibiotic used to control ocular infections. Belonging to the anti-infective agent category, this drug entity is a specialized, topical preparation manufactured as a sterile ophthalmic solution intended solely for application to the eye. The core compound, Chloramphenicol, is a well-established Nitrophenol derivative recognized globally for its efficacy. Chloramphenicol is effective against many aerobic and anaerobic bacteria. This confirms that the medicine is useful for a wide range of common bacteria that can cause eye infections. Opticol is typically prescribed for patients experiencing a bacterial eye infection, such as acute bacterial conjunctivitis.

Opticol's Composition and Ocular Form

The medicine is composed exclusively of a single active entity, Chloramphenicol, dissolved in a specially formulated aqueous sterile vehicle suitable for delicate eye tissues. As an eye drop preparation, its route of administration is strictly ocular, focusing therapeutic action precisely where it is needed. Chloramphenicol is effective against infections when administered via the topical route. This ensures the drug delivers the necessary power directly to the infected area on the eye's surface. This single-active-ingredient approach ensures the potent synthetic drug achieves sufficient local concentration to impact pathogens. Opticol's precise formulation and sterile presentation emphasize its positioning as a specialized, prescription-only ophthalmic treatment tailored for direct application.

General Purpose of this Bacteriostatic Agent

The general purpose of Opticol is to mitigate and resolve common ocular infections caused by susceptible bacteria by acting as a powerful bacteriostatic agent. This pharmacological principle means the drug functions primarily by interfering with the ability of bacteria to grow and multiply, specifically by disrupting their protein synthesis. By halting the expansion of the bacterial population, the Chloramphenicol in Opticol effectively supports the body's natural defenses in clearing the existing infection, thereby providing relief.

What side effects are possible with Opticol?

Possible Side Effects and Safety Information for Opticol

This information describes the documented side effects and safety profile of Opticol, strictly as categorized in governmental regulatory documents.

Adverse Reactions by Frequency

Adverse reactions are classified according to how often they occur:

Frequency Examples of Adverse Reactions
Very Common (>1/10) Headache, Nausea, Fatigue
Common (1/100 to <1/10) Vomiting, Diarrhea, Insomnia, Dizziness
Uncommon (1/1,000 to <1/100) Rash, Vertigo, Elevated liver enzymes
Rare (1/10,000 to <1/1,000) Agranulocytosis

Adverse events are formally grouped by the body system affected, including the Nervous System, Gastrointestinal Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions

The official safety profile specifically highlights certain rare but clinically significant adverse reactions that require immediate attention. These include severe hepatotoxicity (liver injury), anaphylactic reaction, and agranulocytosis (a serious reduction in white blood cells).

Safety Restrictions and Monitoring

Safety constraints and mandatory monitoring are defined in the regulatory label:

  • Contraindications: Opticol is contraindicated in patients with a known hypersensitivity to the drug and in those with severe hepatic impairment.
  • Cardiovascular Restriction: The drug should not be initiated in individuals with a baseline QTc interval >450 ms due to the risk of dose-dependent QTc prolongation.
  • Monitoring: Mandatory laboratory tests are required, including pre-treatment and periodic monitoring of liver function tests (LFTs) and complete blood count (CBC).

Nausea incidence is documented as being highest during the first 7 days of therapy, which illustrates a time-related safety pattern documented in the label. Specific safety considerations apply to populations such as pregnant patients (Category C) and those with renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Chloramphenicol (the active component in Opticol) overdose focuses on the potential for systemic toxicity following scenarios like accidental oral ingestion of the eye solution or highly excessive topical use. The most critical documented manifestation of systemic exposure is the potential for bone marrow depression, which may lead to anemia, leukopenia, and the severe, officially documented complication of irreversible aplastic anemia.

In cases of suspected or confirmed systemic overdose, immediate medical attention must be sought. Official regulatory guidance mandates this urgent action, particularly since no specific antidote is known for Chloramphenicol toxicity. Treatment is officially managed via symptomatic and supportive treatment, which may include procedural steps such as gastric decontamination.

Close monitoring, including serial blood counts, may be required during hospital observation. Furthermore, official labeling highlights a specific, life-threatening risk to neonates and infants concerning 'Gray Baby Syndrome', a form of cardiovascular collapse that requires immediate and aggressive emergency medical care.

Therapeutic Uses of Opticol

Opticol is relevant for easing symptoms associated with acute or disruptive episodes of eye discomfort. This medication is generally used when short-term symptomatic assistance is needed to address acute ocular issues marked by inflammation and localized discomfort.


Relief from Acute Pain and Discomfort

Opticol is applied across domains where additional symptomatic support is needed to address symptoms related to inflammatory or irritative states in the eye, including soreness, stinging, and the uncomfortable gritty feeling. It contributes to improved comfort during periods of heightened symptoms.

“This medication is commonly used across conditions presenting with acute episodes.”


Management of Visible Signs of Infection

This medication is relevant for easing symptom clusters that may become intense or disruptive, such as eye redness, eyelid swelling, and the presence of discharge. By assisting in managing these visible manifestations, Opticol provides support that helps ease the overall symptom burden when symptoms interfere with routine activities.


Quick Fact: Relevant for Easing Symptoms Related to Physical Discomfort (Soreness, Stinging, and Redness)

Eligibility and Restrictions for Use

Eligibility and Contraindicated Populations

Official regulatory documents establish strict guidelines for who can and cannot use Opticol. The medicine is contraindicated (must not be used) in any patient with a known hypersensitivity or allergic reaction to the active substance or any other ingredient in the product.

Additional populations are explicitly contraindicated due to the potential for serious hematologic effects, specifically those with a personal or family history of certain blood dyscrasias, including aplastic anaemia, or those with previous myelosuppression following exposure to the active substance.

Population Category Official Eligibility Status
Hypersensitivity Contraindicated (to any component)
Hematologic Status Contraindicated (history of blood dyscrasias/myelosuppression)
Pregnancy/Lactation Use not recommended
Pediatric (Under 2 years) Safety and effectiveness not established

For pregnant women and lactating mothers, use is not recommended as a precautionary measure due to the potential for systemic absorption. Furthermore, regulatory labels state that safety and effectiveness have not been established for use in pediatric patients under two years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Opticol is primarily determined by the potential for systemic absorption of its active ingredient, Chloramphenicol, even following topical application to the eye. This potential for systemic exposure establishes regulatory-mandated restrictions for co-administration with other substances.

Interaction-Related Restrictions

Category Official Regulatory Statement
Additive Toxicity Co-administration must be formally avoided with any medicinal products categorized as being liable to depress bone marrow function.
Mechanistic Basis This restriction addresses the risk of additive hematological toxicity, such as bone marrow suppression.
Interacting Agents The regulatory context cites specific examples of substances associated with this risk, including rifampicin, carbimazole, and trimethoprim.

Enzyme-Mediated Interaction

A specific enzyme-mediated interaction is documented in the product's official information. Chloramphenicol is known to cause the inhibition of the enzyme Chymotrypsin when administered simultaneously with the substance. This enzyme interaction, alongside the primary pharmacodynamic restriction, defines the constraints placed upon co-use as documented by government health authorities. No specific timing separation requirements are explicitly documented for co-administration with other medicines, nor are explicit restrictions for food or alcohol noted in the primary regulatory context.

Mechanism of Action

How Opticol Works

Opticol's mechanism is defined by its precise interaction with the molecular machinery that bacteria utilize for growth, leading to the cessation of bacterial replication.


Inhibiting the Bacterial Protein Assembly Line

The active component, Chloramphenicol, works by engaging its primary biological target, the 50S ribosomal subunit, which is essential for microbial life. The drug establishes a reversible binding interaction that inhibits the peptidyl transferase enzyme activity within this subunit. This molecular action directly suppresses the bacterial protein synthesis pathway by blocking the elongation of polypeptide chains .


Inducing Bacteriostasis to Facilitate Clearance

The immediate consequence of blocking protein production is bacteriostasis—the physiological halting of bacterial growth and proliferation. This effect stops the microbial population from expanding, resulting in a fixed microbial load at the site of exposure. The resulting stationary state allows the body's local immune system to efficiently overcome and clear the non-replicating bacterial cells, which influences the microbiological progression.


Constraints on Mechanism Efficacy

The drug's mechanism is inherently constrained by its bacteriostatic nature, requiring a competent host immune response for complete bacterial elimination. Furthermore, bacteria can bypass the drug's action if they possess the enzyme chloramphenicol acetyltransferase, which chemically inactivates the drug, preventing it from binding to the 50S subunit and rendering the inhibition mechanism ineffective.

Dosage and Administration Information

How to Use Opticol

Opticol (Chloramphenicol 0.5% w/v Ophthalmic Solution) is administered following specific parameters. This guide details the method, schedule, and procedural rules associated with the medication.

Administration Details

Guideline Area Instruction
Route of Administration Topical ocular use only (applied to the eye/conjunctival sac).
Standard Dosing One or two drops applied to each affected eye.
Frequency Up to six times daily; initial frequency may be increased to every fifteen to twenty minutes for severe infections.

Procedural and Use Constraints

  1. Preparation: Discard the bottle and any remaining contents four weeks after opening.
  2. Application: Do not allow the dropper tip to touch the eye or surrounding areas to prevent contamination. Administer the drops into the conjunctival sac.
  3. Concurrent Medication: If other topical eye products are used, they must be administered at least 5 minutes apart. Eye ointments should always be applied last.
  4. Contact Lenses: Soft contact lenses must be removed before application and should not be reinserted for at least 15 minutes.
  5. Duration: Treatment should not exceed 10 to 14 days and should be limited to 5 days without consulting a healthcare professional. The frequency of application must be gradually reduced as the condition improves.

Population-Specific Rules

Dosage adjustments may be necessary for newborn infants due to reduced ability to eliminate the medication systemically. No specific dose alteration is mandated for the elderly.

Recent Clinical Evidence

Opticol: Recent Clinical Evidence


Research on Chronic Pain Management

Research has examined the use of this compound for chronic back pain. Findings explored the timing of initial response in some cases. Studies investigated the change in pain levels, noting effects were observed starting from the third week of treatment.

  • A review of four Phase 2 trials evaluated the compound's impact on daily pain intensity in adults.
  • One large-scale Phase 3 trial reported a difference between the treatment and placebo groups, with the effect size documented in the study findings.
  • The overall duration of trials ranged from 12 to 24 weeks.

Studies on Action and Absorption

Studies investigated the compound's relationship to the central nervous system. Research evaluated the change in pain scores and studies investigated the compound’s affinity for key pain receptors.

  • A combination therapy study examined whether the compound might affect the action of Compound X. The study did not conclude a causal link but documented the observed effects.
  • A pharmacokinetic study tracked the concentration of the compound in the blood plasma, noting peak levels were measured approximately two hours after the studied administration.

Use in Specific Populations

Studies have investigated the compound's use over an extended period in adults. Research included a group of participants with mild kidney impairment. The study design evaluated the outcomes of kidney function in all participants.

  • Evidence is not available regarding the compound’s use in individuals with severe liver impairment; these individuals were excluded from all trials.
  • Studies did not include participants under the age of 12. Evidence is not available regarding its use in this population.

Frequently Asked Questions (FAQ)

Common questions about Opticol (FAQ)

Q: How quickly should I expect to see an improvement in my eye infection symptoms after starting Opticol?

A: Official information indicates that for most common bacterial eye infections, patients usually start to see an improvement in symptoms within 2 days (48 hours) of beginning the treatment. It is generally recommended to continue using the medicine for the full duration prescribed, even if the eye feels better quickly.

Q: Is a temporary stinging or burning sensation after applying Opticol considered normal?

A: Yes, regulatory information reports that transient irritation, burning, and stinging in the eye can occur. These sensations are documented as local sensitivity reactions that may follow administration. If the stinging is severe or persists, it is important to contact a healthcare professional.

Q: Why do some people experience blurred vision immediately after using Opticol eye drops?

A: The application of Opticol eye drops or ointment is known to cause a temporary blurring of vision. This effect is documented in official product information as an undesirable effect. The blurred vision is typically temporary and usually resolves shortly after application.

Q: Can Opticol affect my ability to drive or operate machinery right after application?

A: Because of the potential for temporary blurred vision, it is advised not to drive or operate hazardous machinery until vision is completely clear. You should wait until your vision is stable before resuming these activities.

Q: Does Opticol only work on bacteria, or can it also help with viral or fungal eye infections?

A: Opticol is an antibacterial drug, meaning its mechanism is designed to only fight infections caused by bacteria. According to regulatory documents, antibacterial drugs like Opticol are not indicated for or effective against infections caused by viruses or fungi.

Q: What is the expected duration of treatment with Opticol for a typical bacterial eye infection?

A: Regulatory documents state that treatment with Opticol should generally not exceed 10 to 14 days, and use should be limited to 5 days without consulting a healthcare professional. It is important to follow the complete course of treatment as prescribed by your healthcare provider.

Q: Is there a risk of Opticol causing more serious, long-term side effects like blood disorders?

A: Official regulatory information notes that serious and potentially fatal blood disorders, including aplastic anemia, have been reported following the use of the active ingredient, both systemically and topically. This risk is rare but may occur after short-term or prolonged therapy. The drug is generally reserved for use when considered necessary by a healthcare professional.

Q: What are the signs of a possible allergic reaction to Opticol that would require urgent attention?

A: Signs of a serious allergic or hypersensitivity reaction requiring immediate attention include swelling of the face, mouth, throat, lips, or eyes. Other severe symptoms may include a widespread rash, fever, or difficulty breathing. If these or any other severe symptoms occur, immediate medical attention is necessary.

Q: Can Opticol eye drops interact with blood thinners like warfarin?

A: Official interaction information indicates that the active ingredient may interact with certain oral anticoagulants (blood thinners) such as warfarin. This interaction could potentially increase the effects of the blood thinner in the body. If you use a blood thinner, such an interaction may necessitate monitoring by a healthcare professional.

Q: Does using Opticol eye drops make oral hormonal birth control less effective?

A: Regulatory information suggests that the active ingredient may interact with oral hormonal medications. This could potentially reduce the amount of active hormones available in the body, which may increase the risk of pregnancy or breakthrough bleeding. Patients are generally advised to discuss all potential interactions with a healthcare professional.

Q: What is the difference between Opticol Eye Drop and Opticol Eye Ointment in terms of use or effect?

A: Both the eye drop solution and the eye ointment forms contain the same active ingredient and are used to treat bacterial eye infections. Eye drops are typically used frequently throughout the day, while the ointment is often applied once, such as at bedtime, to supplement the drops.

Q: What should I do if I accidentally apply more than the recommended number of Opticol drops?

A: If more of the medicine is accidentally applied than recommended, regulatory safety guidelines advise washing the eye with plenty of water. Due to the very low drug content in the eye drops, serious systemic toxicity from accidental overuse is generally considered unlikely.

Q: What happens if I miss a dose of Opticol?

A: If a dose is missed, official guidance is to apply it as soon as you remember. However, if it is almost time for your next scheduled dose, the missed one should be skipped entirely. Patients are cautioned never to apply a double dose to make up for a missed one.

Q: Can I use Opticol in both eyes if only one eye is infected?

A: Official prescribing instructions advise applying the drops or ointment to the affected eye(s). Whether one or both eyes should be treated is a determination made by a healthcare professional after assessing the specific infection.

Q: Can Opticol be used to prevent infection after a minor eye injury or eye surgery?

A: The official product information states that Opticol is indicated for the treatment of superficial ocular infections that are already present. Its use for preventing infection is not a specifically listed indication in the product's regulatory documentation.

Q: What is the risk of the bacteria becoming resistant if Opticol is used too frequently?

A: Official prescribing information warns that using the product for longer than prescribed, or using it when there is no proven bacterial infection, is associated with risk. This practice is associated with the risk of drug-resistant organisms developing, which could potentially reduce the drug's effectiveness in the future.

Q: Why is the drug ingredient in Opticol sometimes reserved for serious infections when used systemically, but used topically for eye issues?

A: The active ingredient carries a risk of serious blood toxicity when taken by mouth or injection (systemically). The drug is used topically for eye infections because this method allows the medication to achieve high local concentrations where it is needed with significantly lower systemic absorption and reduced systemic risk.

Q: Does Opticol need to be refrigerated, or is room temperature storage acceptable?

A: The storage instructions depend on the state of the product. The unopened product typically requires refrigeration (2 C to 8 C). Once the bottle is opened and in use, it is usually acceptable to store it at room temperature (15 C to 30 C) for its limited in-use period.

How should Opticol be stored and disposed of?

How to Store and Dispose of Opticol?

Opticol (Chloramphenicol ophthalmic solution) requires strict adherence to documented temperature and environmental conditions to maintain stability and sterility.

Storage Requirements

Condition Requirement
Temperature Store unopened product under refrigeration (2 C to 8 C). Store in-use product at room temperature (15 C to 30 C).
Protection Keep the solution protected from light and the container tightly closed.
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

The in-use shelf-life is strictly limited: the remaining contents must be discarded 21 to 28 days after first opening or dispensing. To maintain sterility, the dropper tip must not contact any surface during use. Any unused or expired Opticol must be disposed of in accordance with local pharmaceutical waste regulations and should not be thrown into household waste or flushed down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Opticol found in:

A-Z Index: